Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RMHHV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ABBV-969
|
|||||
| Synonyms |
ABBV-969
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-PSMA/STEAP1 IgG1 mAb
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1); Metalloreductase STEAP1 (STEAP1)
|
Antigen Info | ||||
| Payload Name |
A-1770637
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
BrAc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
HY-148820
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Prostate cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must have mCRPC with progression post-NHAs (abiraterone/enzalutamide) and prior taxane therapy, serum testosterone ≤50 ng/dL, measurable disease (RECIST 1.1/PCWG3), PSA ≥1 ng/mL, available tumor tissue, QTc ≤470 msec, and life expectancy >6 months.
|
||||
| Administration Dosage |
Participants will receive escalating doses of ABBV-969.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06318273 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer | ||||
| Primary Endpoint |
The study evaluates safety through AE/SAE monitoring (up to 3 years) and efficacy via PSA response (≥50% decrease) in prostate cancer patients, with all events assessed by investigators for treatment relationship.
|
||||
| Other Endpoint |
Secondary endpoints include PK analysis of ABBV-969, and RP2D determination during dose-escalation (up to 2 years) based on safety/PK data.
|
||||
References